Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Ductus Arteriosus, Patent Clinical Trial

— PIVOTAL  

Official title:

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05547165
• Other study ID #: 00002501
• Secondary ID: UG3HL161338
• Status: Recruiting
• Phase: N/A
• Start date: February 21, 2023
• Est. completion date: February 28, 2026

Study information

• Verified date: November 2023
• Source: Nationwide Children's Hospital
• Contact: Carl H Backes
• Phone: 16143556729
• Email: carl.backes[@]nationwidechildrens.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: February 28, 2026
• Est. primary completion date: February 28, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Days to 32 Days

Eligibility

Inclusion Criteria:

1. EPIs born between 22-weeks+0 days (220/7 wks) and 27-weeks+6 days (276/7 wks) gestation, inclusive

2. Admitted to a study NICU

3. Birth weight =700-grams

4. Mechanically ventilated at time of consent and randomization

5. HSPDA ("PDA Score" =6) noted on echocardiogram (ECHO)

6. Randomization is able to be performed within 5 days of the qualifying ECHO and when infant is 7-32 days postnatal Exclusion Criteria: Clinical Exclusion Criteria

1. Life-threatening congenital defects (including congenital heart disease such as aortic coarctation or pulmonary artery stenosis). PDA and small atrial/ventricular septal defects are permitted;

2. Congenital lung abnormalities, (e.g. restrictive lung disease);

3. Pharyngeal or airway anomalies (tracheal stenosis, choanal atresia);

4. Treatment for acute abdominal process (e.g., necrotizing enterocolitis);

5. Infants with planned surgery;

6. Active infection requiring treatment;

7. Chromosomal defects (e.g., Trisomy 18);

8. Neuromuscular disorders;

9. Infants whose parents have chosen to allow natural death (do not resuscitate order) or for whom limitation of intensive care treatment is being considered (e.g. severe intraventricular hemorrhage)

10. Physician deems that the infant would not be a Percutaneous PDA Closure candidate due to clinical instability; however, if the infant's clinical status improves before 30-days postnatal and all inclusion criteria are still met, then the infant may be enrolled. ECHO-based Exclusion Criteria

1. Pulmonary hypertension (defined by ductal right to left shunting for >33% of the cardiac cycle) in which early PDA closure may increase right ventricular afterload and compromise pulmonary and systemic blood flow;

2. Evidence of cardiac thrombus that might interfere with device placement;

3. PDA diameter larger than 4 mm at the narrowest portion (consistent with FDA-approved instructions for Piccolo™ device use).

4. PDA length smaller than 3 mm (consistent with FDA-approved instructions for Piccolo™ device use).

5. PDA that does not meet inclusion requirements ("PDA Score" <6).* * If a potential participant is found to have a PDA meeting eligibility requirements on a subsequent ECHO during the required period of 7 - 30 postnatal days of age, they may then be declared eligible to participate and enrolled, provided all other inclusion criteria are met and exclusion criteria are not met. Other Exclusion Criteria

1. Parents or legal guardian do not speak English or Spanish

Related Conditions & MeSH terms

• Ductus Arteriosus, Patent

Intervention

Device:
• Percutaneous Patent Ductus Arteriosus Closure (PPC)
Infants in this group will undergo catheter-based PPC closure =48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.

Combination Product:
• Responsive Management Intervention
Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered. Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP).

Diagnostic Test:
• Echocardiogram, cardiac
An echocardiogram, also known as "ECHO", is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions.

Locations

Country	Name	City	State
United States	C.S. Mott Children's Hospital	Ann Arbor	Michigan
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Ann and Robert H. Lurie Children's Hospital	Chicago	Illinois
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Medical City Children's Dallas	Dallas	Texas
United States	UT Southwestern Children's Medical Center of Dallas	Dallas	Texas
United States	Joe DiMaggio Children's Hospital	Hollywood	Florida
United States	Texas Children's	Houston	Texas
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Le Bonheur Children's Medical Center	Memphis	Tennessee
United States	Children's Wisconsin	Milwaukee	Wisconsin
United States	University of Minnesota, Masonic Children's Hospital	Minneapolis	Minnesota
United States	Monroe Carell Jr. Children's Hospital at Vanderbilt	Nashville	Tennessee
United States	Morgan Stanley Children's Hospital of New York-Presbyterian	New York	New York
United States	Orlando Health	Orlando	Florida
United States	Lucille Packard Children's Hospital at Stanford	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	UC Davis Children's Hospital	Sacramento	California
United States	St. Louis Children's Hospital	Saint Louis	Missouri
United States	Seattle Children's	Seattle	Washington

Sponsors (11)

Lead Sponsor	Collaborator
Nationwide Children's Hospital	Abbott, Cedars-Sinai Medical Center, Children's Hospital Los Angeles, Dartmouth College, Emory University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), University of Bristol, University of Iowa, University of Pittsburgh

Country where clinical trial is conducted

United States, 

References & Publications (28)

Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986 Dec;51(6):1173-82. doi: 10.1037//0022-3514.51.6.1173. — View Citation

Benitz WE. Patent ductus arteriosus: to treat or not to treat? Arch Dis Child Fetal Neonatal Ed. 2012 Mar;97(2):F80-2. doi: 10.1136/archdischild-2011-300381. Epub 2011 Dec 15. — View Citation

Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-3730. Epub 2015 Dec 15. — View Citation

Coyne IT. Sampling in qualitative research. Purposeful and theoretical sampling; merging or clear boundaries? J Adv Nurs. 1997 Sep;26(3):623-30. doi: 10.1046/j.1365-2648.1997.t01-25-00999.x. — View Citation

Donovan JL, de Salis I, Toerien M, Paramasivan S, Hamdy FC, Blazeby JM. The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. J Clin Epidemiol. 2014 Aug;67(8):912-20. doi: 10.1016/j.jclinepi.2014.03.010. Epub 2014 May 5. — View Citation

Donovan JL, Lane JA, Peters TJ, Brindle L, Salter E, Gillatt D, Powell P, Bollina P, Neal DE, Hamdy FC; ProtecT Study Group. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol. 2009 Jan;62(1):29-36. doi: 10.1016/j.jclinepi.2008.02.010. Epub 2008 Jul 10. — View Citation

Donovan JL, Paramasivan S, de Salis I, Toerien M. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials. 2014 Jan 6;15:5. doi: 10.1186/1745-6215-15-5. — View Citation

Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, Mills N, Wilson C, Paramasivan S, Blazeby JM. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016 Jun 8;17(1):283. doi: 10.1186/s13063-016-1391-4. — View Citation

Glaser BG, Strauss AL. The Discovery of Grounded Theory: Strategies for Qualitative Research. Vol. ed.: Aldine; 1967.

Gordon Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659-663.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14. — View Citation

Jensen EA, DeMauro SB, Kornhauser M, Aghai ZH, Greenspan JS, Dysart KC. Effects of Multiple Ventilation Courses and Duration of Mechanical Ventilation on Respiratory Outcomes in Extremely Low-Birth-Weight Infants. JAMA Pediatr. 2015 Nov;169(11):1011-7. doi: 10.1001/jamapediatrics.2015.2401. — View Citation

Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM, Birtle A, Halliday A, Stein R, Donovan JL; CSAW study group; Chemorad study group; POUT study group; ACST-2 study group; OPTIMA prelim study group. An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. J Clin Epidemiol. 2018 Jul;99:75-83. doi: 10.1016/j.jclinepi.2018.02.018. Epub 2018 Mar 2. — View Citation

L Orton J, McGinley JL, Fox LM, Spittle AJ. Challenges of neurodevelopmental follow-up for extremely preterm infants at two years. Early Hum Dev. 2015 Dec;91(12):689-94. doi: 10.1016/j.earlhumdev.2015.09.012. Epub 2015 Oct 27. — View Citation

Lawrence CE, Dunkel L, McEver M, Israel T, Taylor R, Chiriboga G, Goins KV, Rahn EJ, Mudano AS, Roberson ED, Chambless C, Wadley VG, Danila MI, Fischer MA, Joosten Y, Saag KG, Allison JJ, Lemon SC, Harris PA. A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent. J Clin Transl Sci. 2020 Apr 3;4(4):345-353. doi: 10.1017/cts.2020.30. — View Citation

Liebowitz M, Katheria A, Sauberan J, Singh J, Nelson K, Hassinger DC, Aucott SW, Kaempf J, Kimball A, Fernandez E, Carey WA, Perez J, Serize A, Wickremasinghe A, Dong L, Derrick M, Wolf IS, Heuchan AM, Sankar M, Bulbul A, Clyman RI; PDA-TOLERATE (PDA: TOLEave it alone or Respond And Treat Early) Trial Investigators. Lack of Equipoise in the PDA-TOLERATE Trial: A Comparison of Eligible Infants Enrolled in the Trial and Those Treated Outside the Trial. J Pediatr. 2019 Oct;213:222-226.e2. doi: 10.1016/j.jpeds.2019.05.049. Epub 2019 Jun 27. — View Citation

Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA. Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol. 2011 Oct;64(10):1127-36. doi: 10.1016/j.jclinepi.2010.12.017. Epub 2011 Apr 7. — View Citation

O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56. — View Citation

Paramasivan S, Strong S, Wilson C, Campbell B, Blazeby JM, Donovan JL. A simple technique to identify key recruitment issues in randomised controlled trials: Q-QAT - Quanti-Qualitative Appointment Timing. Trials. 2015 Mar 11;16:88. doi: 10.1186/s13063-015-0617-1. — View Citation

Rooshenas L, Elliott D, Wade J, Jepson M, Paramasivan S, Strong S, Wilson C, Beard D, Blazeby JM, Birtle A, Halliday A, Rogers CA, Stein R, Donovan JL; ACST-2 study group; By-Band-Sleeve study group; Chemorad study group; CSAW study group; Optima prelim study group; POUT study group. Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials. PLoS Med. 2016 Oct 18;13(10):e1002147. doi: 10.1371/journal.pmed.1002147. eCollection 2016 Oct. — View Citation

Rooshenas L, Paramasivan S, Jepson M, Donovan JL. Intensive Triangulation of Qualitative Research and Quantitative Data to Improve Recruitment to Randomized Trials: The QuinteT Approach. Qual Health Res. 2019 Apr;29(5):672-679. doi: 10.1177/1049732319828693. Epub 2019 Feb 22. — View Citation

Rooshenas L, Scott LJ, Blazeby JM, Rogers CA, Tilling KM, Husbands S, Conefrey C, Mills N, Stein RC, Metcalfe C, Carr AJ, Beard DJ, Davis T, Paramasivan S, Jepson M, Avery K, Elliott D, Wilson C, Donovan JL; By-Band-Sleeve study group; CSAW study group; HAND-1 study group; Optima prelim study group; Romio feasibility study group. The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. J Clin Epidemiol. 2019 Feb;106:108-120. doi: 10.1016/j.jclinepi.2018.10.004. Epub 2018 Oct 16. — View Citation

Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Vol. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2014.

US Food and Drug Administration. Use of electronic informed consent, questions and answers: Guidance for institutional review boards, investigators, and sponsors. Silver Spring, MD: US Food and Drug Administration. 2016.

Vliegenthart RJS, van Kaam AH, Aarnoudse-Moens CSH, van Wassenaer AG, Onland W. Duration of mechanical ventilation and neurodevelopment in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2019 Nov;104(6):F631-F635. doi: 10.1136/archdischild-2018-315993. Epub 2019 Mar 20. — View Citation

Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond "p< 0.05". In. Vol 73: Taylor & Francis; 2019:1-19.

Watterberg KL, Walsh MC, Li L, Chawla S, D'Angio CT, Goldberg RN, Hintz SR, Laughon MM, Yoder BA, Kennedy KA, McDavid GE, Backstrom-Lacy C, Das A, Crawford MM, Keszler M, Sokol GM, Poindexter BB, Ambalavanan N, Hibbs AM, Truog WE, Schmidt B, Wyckoff MH, Khan AM, Garg M, Chess PR, Reynolds AM, Moallem M, Bell EF, Meyer LR, Patel RM, Van Meurs KP, Cotten CM, McGowan EC, Hines AC, Merhar S, Peralta-Carcelen M, Wilson-Costello DE, Kilbride HW, DeMauro SB, Heyne RJ, Mosquera RA, Natarajan G, Purdy IB, Lowe JR, Maitre NL, Harmon HM, Hogden LA, Adams-Chapman I, Winter S, Malcolm WF, Higgins RD; Eunice Kennedy Shriver NICHD Neonatal Research Network. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. N Engl J Med. 2022 Mar 24;386(12):1121-1131. doi: 10.1056/NEJMoa2114897. — View Citation

Wilson C, Rooshenas L, Paramasivan S, Elliott D, Jepson M, Strong S, Birtle A, Beard DJ, Halliday A, Hamdy FC, Lewis R, Metcalfe C, Rogers CA, Stein RC, Blazeby JM, Donovan JL. Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. Trials. 2018 Jan 19;19(1):50. doi: 10.1186/s13063-017-2413-6. — View Citation

* Note: There are 28 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Determine whether neurodevelopment at 3-4 months CA is mediated by improved neurodevelopmental profiles at 34-36 weeks PMA.	Analysis of HNNE / HINE scores to determine if neurodevelopmental evaluation scores conducted at 34 - 36 weeks post-menstrual age mediate outcomes at 3 - 4 months corrected age	34-36 weeks post-menstrual age and 3 - 4 months corrected age
Other	Evaluation of effect modifiers on primary and secondary outcomes	Examination of the homogeneity of the effect of HSPDA on the primary and secondary outcomes will be carried out in statistical analyses using stratification variables (e.g., gender, gestational age, etc.) and characteristics not balanced through random assignment, if any such imbalances are found.	Birth to 4 months of corrected age
Primary	Number of days free of ventilatory support requirement (ventilator-free days; VFDs)	Ventilator free days (VFDs) are defined as the number of days that a subject is alive and free from mechanical ventilatory support. VFDs are an established respiratory outcome measure in pediatric clinical trials, and are a strong predictor of short-term and longer-term oucomes, including length of neonatal intensive care unit (NICU) stay, morbidities, and mortality.	30 days post-randomization
Secondary	Positive-pressure dependency or death	A composite outcome measure (yes/no), positive pressure dependency at 36 weeks post-menstrual age (PMA) is an indicator of chronic lung disease (CLD), the most common and serious respiratory complication of prematurity. Both invasive and non-invasive positive pressure ventilation at 36 weeks PMA is associated with long-term respiratory and neurodevelopmental impairment.	36 weeks post-menstrual age
Secondary	Diagnosis of pulmonary hypertension or death	A compositve binary outcome measure (yes/no), diagnosis of pulmonary hypertension will be determined by cardiac echocardiogram at 36 weeks post-menstrual age. Diagnosis of pulmonary hypertension is an indicator of increased pulmonary vasculature resistance, a marker for increased morbidity and mortality among infants with chronic lung disease.	36 weeks post-menstrual age
Secondary	Total days on mechanical ventilation	The total number of days (continuous variable) a study subject requires any use of invasive mechanical ventilatory support within a 24-hour calendar day.	4 months corrected age
Secondary	Days requiring positive-pressure assisted breathing	The sum of days the study subject requires either invasive or non-invasive positive pressure assisted ventilation within a 24 hour calendar day.	Randomization through 4 months corrected age
Secondary	Days on supplemental oxygen	Total number of days the study subject requires supplemental oxygen. The subject may be on either invasive or non-invasive ventilatory support during this time. The subject must be free from supplemental oxygen use for a period of at least 24 hours to interrupt or cease counting.	Randomization through 4 months corrected age
Secondary	Time to death	A continuous measure, in days, of the time from a study subject's randomization to expiration, if this occurs.	Randomization through 4 months corrected age
Secondary	Diagnosis of cardiac dysfunction	A diagnosis of left-ventricular output by echocardiography (ECHO) at 36 weeks post-menstrual age.	36 weeks post-menstrual age
Secondary	Abnormal cardiac remodeling	Finding of left-ventricular end-diastolic volume (LV EDV) >97% on echocardiography (ECHO) at 36 weeks post-menstrual age.	36 weeks post-menstrual age
Secondary	General Movements Assessment (GMA)	The General Movements Assessment (GMA) is a standardized video-based neurological exam to evaluate the presence of "fidgety" versus "absent fidgety" and "cramped-synchronized" versus "non cramped-synchronized" movement patterns at 34 - 36 weeks post-menstrual age. It is used to assist in the diagnosis of impaired motor neurodevelopment and cerebral palsy.	34 - 36 weeks post-menstrual age
Secondary	Need for rescue intervention	Recording of incidence of need for study subjects randomized to Responsive Management to undergo Percutaneous Patent Ductus Arteriosus Closure (PPC) due to decline in health status.	Randomization through 4 months corrected age
Secondary	Hammersmith Neonatal Neurological Examination (HNNE)	The HNNE is a standardized neurological examination of 34 items to evaluate tone, motor patterns, spontaneous movements, reflexes, visual and auditory attention, and behavior.	34 - 36 weeks post-menstrual age
Secondary	Hammersmith Infant Neurological Examination (HINE)	The HINE is similar to the HNNE, used to assess neurological function at 3 - 24 months of age, including cranial nerve function, movements, reflexes, protective reactions and behavior, and age-dependent evaluation of gross and fine-motor function.	3 - 4 months of corrected age
Secondary	Infant/Toddler Sensory Profile (Low Registration Domain)	Caregiver questionnaire responses to determine if their infant appropriately processes and responds to environmental stimuli, versus missing or taking longer to respond ("Low Registration"). There are 13 items with scores of 13 - 65 possible; scores of 42 - 51 are considered "Typical performance".	3 - 4 months of corrected age
Secondary	Infant/Toddler Sensory Profile (Sensation Seeking Domain)	Caregiver questionnaire responses to determine if their infant is hyposensitive, seeking additional sensory stimulation. There are 6 items with scores of 6 - 30 possible; scores of 7 - 15 are considered "Typical performance".	3 - 4 months of corrected age
Secondary	Infant/Toddler Sensory Profile (Sensory Sensitivity Domain)	Caregiver questionnaire responses to determine if their infant responds readily to sensory stimulation, without actively avoiding it. There are 12 items with scores of 12 - 60 possible; scores of 45 - 57 are considered "Typical performance)	3 - 4 months of corrected age
Secondary	Infant/Toddler Sensory Profile (Sensation Avoiding Domain)	Caregiver questionnaire responses to determine if their infant avoids sensory stimulation. There are 5 items with scores of 5 - 25 possible; scores of 19 - 25 are considered "Typical performance".	3 - 4 months of corrected age
Secondary	Infant/Toddler Sensory Profile (Low Threshold Domain)	Caregiver questionnaire responses which are the sum of the Sensory Sensitivity and Sensation Avoiding domains). Summed scores of 15 - 85 are possible; summed scores of 64 - 81 are considered "Typical performance".	3 - 4 months of corrected age
Secondary	Baby Care Questionnaire (BCQ)	The BCQ is another caregiver-based questionnaire for parental perspectives of an infant's feeding and sleeping habits. It is used as an evaluation of a parent's reliance upon structure / routines and attunement (dependence upon infant's cues).	3 - 4 months of corrected age
Secondary	Mother-Infant Bonding Scale (MIBS)	The MIBS is an 8-item questionnaire to evaluate a mother's bondedness towards her infant. Responses are scored from 0 to 3 for each item, with a total possible range of 0 - 24. Lower scores indicate more favorable outcomes for mother-infant bondedness, whereas higher scores indicate the potential for difficulties.	3 - 4 months of corrected age
Secondary	Type and incidence of any adverse event	Reporting of type and frequency of any adverse event that occurs during percutaneous closure procedures, and post-procedurally that may be related to the intervention.	3 - 4 months of corrected age
Secondary	Type and incidence of serious adverse event	Reporting of type and frequency of any serious adverse event (e.g., potentially life-threatening change in status) that occurs during percutaneous closure procedures, and post-procedurally that may be related to the intervention.	3 - 4 months of corrected age